Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the transaction, the director now owns 3,344,157 shares of the company’s stock, valued at approximately $112,062,701.07. The trade was a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Simulations Plus Trading Down 2.3 %

Shares of NASDAQ SLP opened at $33.56 on Friday. Simulations Plus, Inc. has a twelve month low of $23.01 and a twelve month high of $51.22. The company has a market capitalization of $674.93 million, a price-to-earnings ratio of 83.90 and a beta of 1.13. The firm has a 50-day moving average of $28.58 and a two-hundred day moving average of $30.36.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.25 by $0.06. The business had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. Simulations Plus’s revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 earnings per share. As a group, research analysts predict that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

SLP has been the subject of several recent research reports. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. StockNews.com raised Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday. Finally, KeyCorp raised their target price on shares of Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, April 16th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Hedge Funds Weigh In On Simulations Plus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its holdings in shares of Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after purchasing an additional 427 shares in the last quarter. Fifth Third Bancorp lifted its stake in Simulations Plus by 33.8% in the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock worth $36,000 after acquiring an additional 375 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in Simulations Plus during the 4th quarter worth about $39,000. Tower Research Capital LLC TRC grew its stake in Simulations Plus by 42.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after acquiring an additional 764 shares in the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Simulations Plus by 502.9% in the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after purchasing an additional 2,243 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.